iBio Receives Notice of Allowance for US Patent Application 17/821,295 Titled "Anti-CD-25 Antibody for the Treatment of Cancer"
$IBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2024 | $5.00 | Buy | Chardan Capital Markets |
| 11/29/2021 | $1.50 | Mkt Outperform | JMP Securities |
| 11/29/2021 | $1.50 | Outperform | JMP Securities |
SC 13G/A - iBio, Inc. (0001420720) (Subject)
SC 13G - iBio, Inc. (0001420720) (Subject)
SC 13G - iBio, Inc. (0001420720) (Subject)
3 - iBio, Inc. (0001420720) (Issuer)
4 - iBio, Inc. (0001420720) (Issuer)
4 - iBio, Inc. (0001420720) (Issuer)
– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets – – Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration – – Company to host webcasted conference call today at 8:30 a.m. EDT to discuss AstralBio collaboration – BRYAN, Texas and SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company") announces today that it has entered into a collaboration agreement with AstralBio,
BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announces preliminary unaudited financial results for the fiscal year ended June 30, 2022, and provides a corporate update. "We have continued to take important steps toward achieving our strategic objective of becoming a leading biotechnology company with a focus on developing innovative immunotherapies," said Tom Isett, Chairman & CEO of iBio. "Chief among these was the RubrYc asset acquisition, which provides us with a differentiated, AI-powered drug di
– Positions Company for leadership in AI-powered drug discovery – – Expands iBio's immuno-oncology pipeline with three new candidates – – Hosting investor call on September 27th to discuss transaction, the Company's transformation and FY2022 financial results – SAN DIEGO and BRYAN, Texas, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announced that it closed on the acquisition of substantially all of the assets of its partner, RubrYc Therapeutics, Inc. ("RubrYc") after it entered into a definitive asset purchase agreement (the
Chardan Capital Markets initiated coverage of iBio with a rating of Buy and set a new price target of $5.00
JMP Securities initiated coverage of iBio with a rating of Mkt Outperform and set a new price target of $1.50
JMP Securities initiated coverage of iBio with a rating of Outperform and set a new price target of $1.50
8-K - iBio, Inc. (0001420720) (Filer)
DEF 14A - iBio, Inc. (0001420720) (Filer)
10-K/A - iBio, Inc. (0001420720) (Filer)
Brookline Capital analyst Kemp Dolliver initiates coverage on iBio (AMEX:IBIO) with a Buy rating and announces Price Target of $3.6.
https://patentcenter.uspto.gov/applications/17821295/ifw/docs
Chardan Capital analyst Keay Nakae maintains iBio (AMEX:IBIO) with a Buy and maintains $5 price target.
SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today provided an update on the myostatin program for cardiometabolic disease and obesity in collaboration with AstralBio. iBio's technology stack enabled the Company to rapidly advance the joint myostatin program from inception to in vitro proof-of-concept in human muscle cells. Following early discovery, the companies have identified a molecule with therapeutic potential for treating muscle wasting and obesity, which is designed for subcutaneous administration and has potential for an extended half-life. The companies are currently working on plans to advanc
SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update. "Our fiscal year 2024 was a transformational year for iBio, as we've solidified our business and financial position as a next-generation antibody company with a machine-learning-enabled platform for designing and developing difficult-to-drug therapeutics," said CEO and Chief Scientific Officer Martin Brenner, Ph.D., DVM. "We made significant progress entering the fast-growing cardiometabolic and obesity space with our collaboration with AstralBio a
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today that CEO and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., and Chief Financial Officer, Felipe Duran, will participate in upcoming investor conferences. Dr. Brenner will give a virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference, held at the Lotte New York Palace Hotel in New York City, September 9-11, 2024. The presentation will be available on-demand from 7 a.m., Sept. 9, at https://journey.ct.events/view/5a0ac133-a550-4997-9da1-dc0b394219bf and following for 30 days. A replay of the webcast will be
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of Kristi Sarno as senior vice president, business development. Ms. Sarno brings more than 25 years of business development and strategic experience in the life sciences industry to iBio and will play a key role on the leadership team in establishing the company's corporate strategy and leading business development activities, including overseeing search and evaluation and transaction execution. Before joining iBio, Ms. Sarno held key positions in business development, strategic alliance, program management and research at lead
– Board appointments solidify management team to lead iBio's AI-powered biotech strategy – BRYAN, Texas and SAN DIEGO, June 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), an AI-driven innovator of precision antibody immunotherapies, today announced the appointments of Martin Brenner, DVM, Ph.D. as Chief Executive Officer; and Felipe Duran as Chief Financial Officer, effective immediately. Dr. Brenner will also continue to serve as iBio's Chief Scientific Officer, a role he has held since December 2020. The permanent appointments reflect the Board of Directors' confidence in Dr. Brenner and Mr. Duran, who have respectively served as iBio's interim CEO
Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, today announced the appointment of Evert (Eef) Schimmelpennink to its Board of Directors. Mr. Schimmelpennink is a seasoned biotechnology executive with close to 25 years of experience spanning research and development, commercial growth, manufacturing, and business development. "I am pleased to welcome Eef Schimmelpennink to Pipeline's Board of Directors," said Carmine Stengone, President and Chief Executive Officer of Pipeline Therapeutics. "Eef is a renowned leader in the life-sciences industry whose cross-functional leade